Related Experiment Video
Updated: Aug 16, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
Viral proteases and phosphorodiesterase inhibitors
1Current Drugs Ltd, Middlesex House, London W1P 6LB, United Kingdom. petera@cursci.co.uk
Abstract:
A number of novel drug candidates, which are at different stages of development and various therapeutic targets, mechanisms of action and clinical data were discussed in depth. Crystallographic studies and structures of several viral proteases were outlined and described. AG7088 (Agouron Pharmaceuticals Inc) has been developed as a potent, selective human rhinovirus (HRV)3C protease inhibitor, which has now advanced to phase II trials. Vertex Pharmaceuticals Inc has also made significant progress with a series of non-reversible hepatitis C virus (HCV)inhibitors, which were synthesized by solid-phase methods. The pharmacological profile of CI1018 (Parke-Davis (France)), which is in phase I trials for the treatment of asthma, was described as well as the synthesis of potent back-up compounds, 4-oxo-1-phenyl-3,4,6,7-tetrahydro-(1,2)-diazepino[6,7,1-hi]indoles. Other phosphorodiesterase (PDE)4 inhibitors discussed include: SB207499 (SmithKline Beecham plc), now in phase III trials for chronic obstructive pulmonary disease (COPD); and, RP73401, which was in phase II trials for asthma but has been discontinued.
Related Concept Videos
Inhibitors of Virion Maturation and Assembly
Antiviral Nucleoside Inhibitors
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Subviral Agents
Retrovirus Life Cycles

